Page 112 - Read Online

Page 290 Cencioni. Neuroimmunol Neuroinflammation 2020;7:277-90 I http://dx.doi.org/10.20517/2347-8659.2020.18

autoimmune encephalomyelitis. Cell Immunol 2005;237:123-30.
83. Olivares-Villagómez D, Wang Y, Lafaille JJ. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin
basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med 1998;188:1883-94.
84. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with
multiple sclerosis. J Exp Med 2004;199:971-9.
85. Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, et al. Selective targeting of B cells with agonistic anti-CD40 is an
efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol
2009;182:3492-502.
86. Mauri C, Blair PA. Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol 2010;6:636-43.
87. Schafflick D, Xu CA, Hartlehnert M, Cole M, Schulte-Mecklenbeck A, et al. Integrated single cell analysis of blood and cerebrospinal
fluid leukocytes in multiple sclerosis. Nat Commun 2020;11:247.
88. Guo J, Zhao C, Wu F, Tao L, Zhang C, et al. T follicular helper-like cells are involved in the pathogenesis of experimental autoimmune
encephalomyelitis. Front Immunol 2018;9:944.
89. Shi J, Hou S, Fang Q, Liu X, Liu X, et al. PD-1 controls follicular T helper cell positioning and function. Immunity 2018;49:264-74.e4.
90. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and
infection. Nature 2015;523:612-6.
91. Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, et al. Differential role of programmed death-ligand 1 [corrected] and programmed
death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J
Immunol 2006;176:3480-9.
92. Kroner A, Schwab N, Ip CW, Ortler S, Göbel K, et al. Accelerated course of experimental autoimmune encephalomyelitis in PD-1-
deficient central nervous system myelin mutants. Am J Pathol 2009;174:2290-9.
93. Carter LL, Leach MW, Azoitei ML, Cui J, Pelker JW, et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of
experimental autoimmune encephalomyelitis. J Neuroimmunol 2007;182:124-34.
94. Pittet CL, Newcombe J, Antel JP, Arbour N. The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to
enhanced PD-L1 levels on CNS cells. Glia 2011;59:841-56.
95. Chang CB, Lee SP, Chen WM, Wang CM, Song YC, et al. Dendritic cell upregulation of programmed death ligand-1 via DNA
demethylation inhibits experimental autoimmune encephalomyelitis. J Autoimmun 2019:102362.
96. Jiang TT, Martinov T, Xin L, Kinder JM, Spanier JA, et al. Programmed death-1 culls peripheral accumulation of high-affinity
autoreactive CD4 T cells to protect against autoimmunity. Cell Rep 2016;17:1783-94.
97. Mathis D, Benoist C. Aire. Annu Rev Immunol 2009;27:287-312.
98. Bautista JL, Lio CW, Lathrop SK, Forbush K, Liang Y, et al. Intraclonal competition limits the fate determination of regulatory T cells in
the thymus. Nat Immunol 2009;10:610-7.
99. Leung MW, Shen S, Lafaille JJ. TCR-dependent differentiation of thymic Foxp3+ cells is limited to small clonal sizes. J Exp Med
2009;206:2121-30.
100. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through
PD-1 and CTLA-4. Nat Immunol 2005;6:280-6.
101. Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, et al. A PD-1 polymorphism is associated with disease progression in
multiple sclerosis. Ann Neurol 2005;58:50-7.
102. Javan MR, Aslani S, Zamani MR, Rostamnejad J, Asadi M, et al. Downregulation of immunosuppressive molecules, PD-1 and PD-L1 but
not PD-L2, in the patients with multiple sclerosis. Iran J Allergy Asthma Immunol 2016;15:296-302.
103. Pawlak-Adamska E, Nowak O, Karabon L, Pokryszko-Dragan A, Partyka A, et al. PD-1 gene polymorphic variation is linked with first
symptom of disease and severity of relapsing-remitting form of MS. J Neuroimmunol 2017;305:115-27.
104. Mohammadzadeh A, Rad IA, Ahmadi-Salmasi B. CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients. J
Neuroimmunol 2018;323:105-8.
105. Cencioni MT, Magliozzi R, Nicholas R, Ali R, Malik O, et al. Programmed death 1 is highly expressed on CD8+ CD57+ T cells in
patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. Immunology 2017;152:660-76.
106. Arruda LCM, de Azevedo JTC, de Oliveira GLV, Scortegagna GT, Rodrigues ES, et al. Immunological correlates of favorable long-term
clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation. Clin Immunol 2016;169:47-57.
107. Pittet CL, Newcombe J, Prat A, Arbour N. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand
expression in multiple sclerosis. J Neuroinflammation 2011;8:155.
108. Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult
Scler 2015;21:670.
109. Cao Y, Nylander A, Ramanan S, Goods BA, Ponath G, et al. CNS demyelination and enhanced myelin-reactive responses after
ipilimumab treatment. Neurology 2016;86:1553-6.
110. Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer
2014;2:35.
111. Gerdes LA, Held K, Beltrán E, Berking C, Prinz JC, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis.
Ann Neurol 2016;80:294-300.
112. Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL. Multiple Sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol
2019; Epub 2019 Feb 20.
113. Isitan C, Wesley S. Safety of checkpoint inhibitors for cancer treatment in patients with multiple sclerosis: a case report (P1.7-006).
Neurology 2019;92 (15 Supplement):P1.7-006.